Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
988
datasets available to search
ShareScore release 0.9.0
Dataset results
988 results for “platinum”
Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastati
ClinicalTrials.gov study NCT03515837. IPD Sharing: YES. Countries: 17. Publications: 1.
Study of Magrolimab (Hu5F9-G4) in Combination With Avelumab in Solid Tumor Participants and Checkpoint-Inhibitor-Naive Ovarian Cancer Participants Who Progress Within 6 Months of Prior Platinum Chemot
ClinicalTrials.gov study NCT03558139. IPD Sharing: NO. Countries: 1. Publications: 0.
Phase II Multicenter Study of Durvalumab and Olaparib in Platinum tReated Advanced Triple Negative Breast Cancer (DORA)
ClinicalTrials.gov study NCT03167619. IPD Sharing: NO. Countries: 1. Publications: 1.
Dose-finding Study in Platinum-Resistant Ovarian Cancer
ClinicalTrials.gov study NCT01653912. IPD Sharing: Not stated. Countries: 3. Publications: 1.
Platinum for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response
ClinicalTrials.gov study NCT00483223. IPD Sharing: NO. Countries: 1. Publications: 1.
Afatinib Monotherapy in Patients With ERBB-deregulated Metastatic Urothelial Tract Carcinoma After Failure of Platinum Based Chemotherapy
ClinicalTrials.gov study NCT02780687. IPD Sharing: Not stated. Countries: 3. Publications: 1.
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
ClinicalTrials.gov study NCT01874353. IPD Sharing: YES. Countries: 17. Publications: 7.
Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer
ClinicalTrials.gov study NCT02865811. IPD Sharing: NO. Countries: 1. Publications: 1.
Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy
ClinicalTrials.gov study NCT02184195. IPD Sharing: YES. Countries: 12. Publications: 8.
MAPS Trial: Matrix And Platinum Science
ClinicalTrials.gov study NCT00396981. IPD Sharing: Not stated. Countries: 11. Publications: 2.
A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU)
ClinicalTrials.gov study NCT03033511. IPD Sharing: YES. Countries: 41. Publications: 1.
Pralatrexate and Docetaxel in Treating Patients With Stage IV Esophageal or Gastroesophageal Cancer Who Have Failed Platinum-Based Therapy
ClinicalTrials.gov study NCT01129206. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Study of Chemotherapy and Ramucirumab Versus Chemotherapy Alone in Second Line Non-Small Cell Lung Cancer (NSCLC) Participants Who Received Prior First Line Platinum-based Chemotherapy
ClinicalTrials.gov study NCT01168973. IPD Sharing: YES. Countries: 27. Publications: 4.
An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV
ClinicalTrials.gov study NCT02477826. IPD Sharing: Not stated. Countries: 33. Publications: 7.
A Study to Assess the Safety and Efficacy of ASP1650, a Monoclonal Antibody Targeting Claudin 6 (CLDN6), in Male Subjects With Incurable Platinum Refractory Germ Cell Tumors
ClinicalTrials.gov study NCT03760081. IPD Sharing: NO. Countries: 1. Publications: 1.
Trial of Decitabine as a Sensitizer to Carboplatin in Platinum Resistant Recurrent Ovarian Cancer
ClinicalTrials.gov study NCT00477386. IPD Sharing: Not stated. Countries: 1. Publications: 2.
A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
ClinicalTrials.gov study NCT02655016. IPD Sharing: NO. Countries: 14. Publications: 11.
Pertuzumab in Platinum-Resistant Low Human Epidermal Growth Factor Receptor 3 (HER3) Messenger Ribonucleic Acid (mRNA) Epithelial Ovarian Cancer (PENELOPE)
ClinicalTrials.gov study NCT01684878. IPD Sharing: Not stated. Countries: 10. Publications: 1.
A Study of Pembrolizumab (MK-3475) Plus Platinum and Gemcitabine as First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (PIPER)
ClinicalTrials.gov study NCT05286619. IPD Sharing: YES. Countries: 1. Publications: 1.
Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer
ClinicalTrials.gov study NCT02431559. IPD Sharing: NO. Countries: 2. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.